TY - JOUR
T1 - Forecasting the future economic burden of current adolescent overweight
T2 - An estimate of the coronary heart disease policy model
AU - Lightwood, James
AU - Bibbins-Domingo, Kirsten
AU - Coxson, Pamela
AU - Wang, Y. Claire
AU - Williams, Lawrence
AU - Goldman, Lee
PY - 2009/12/1
Y1 - 2009/12/1
N2 - Objectives. We predicted the future economic burden attributable to high rates of current adolescent overweight. Methods. We constructed models to simulate the costs of excess obesity and associated diabetes and coronary heart disease (CHD) among adults aged 35-64 years in the US population in 2020 to 2050. Results. Current adolescent overweight is projected to result in 161 million lifeyears complicated by obesity, diabetes, or CHD and 1.5 million life-years lost. The cumulative excess attributable total costs are estimated at $254 billion: $208 billion because of lost productivity from earlier death or morbidity and $46 billion from direct medical costs. Currently available therapies for hypertension, hyperlipidemia, and diabetes, used according to guidelines, if applied in the future, would result in modest reductions in excess mortality (decreased to 1.1 million life-years lost) but increase total excess costs by another $7 billion (increased to $261 billion total). Conclusions. Current adolescent overweight will likely lead to large future economic and health burdens, especially lost productivity from premature death and disability. Application of currently available medical treatments will not greatly reduce these future burdens of increased adult obesity.
AB - Objectives. We predicted the future economic burden attributable to high rates of current adolescent overweight. Methods. We constructed models to simulate the costs of excess obesity and associated diabetes and coronary heart disease (CHD) among adults aged 35-64 years in the US population in 2020 to 2050. Results. Current adolescent overweight is projected to result in 161 million lifeyears complicated by obesity, diabetes, or CHD and 1.5 million life-years lost. The cumulative excess attributable total costs are estimated at $254 billion: $208 billion because of lost productivity from earlier death or morbidity and $46 billion from direct medical costs. Currently available therapies for hypertension, hyperlipidemia, and diabetes, used according to guidelines, if applied in the future, would result in modest reductions in excess mortality (decreased to 1.1 million life-years lost) but increase total excess costs by another $7 billion (increased to $261 billion total). Conclusions. Current adolescent overweight will likely lead to large future economic and health burdens, especially lost productivity from premature death and disability. Application of currently available medical treatments will not greatly reduce these future burdens of increased adult obesity.
UR - http://www.scopus.com/inward/record.url?scp=72249115424&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=72249115424&partnerID=8YFLogxK
U2 - 10.2105/AJPH.2008.152595
DO - 10.2105/AJPH.2008.152595
M3 - Article
C2 - 19833999
AN - SCOPUS:72249115424
SN - 0090-0036
VL - 99
SP - 2230
EP - 2237
JO - American Journal of Public Health
JF - American Journal of Public Health
IS - 12
ER -